Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel

PHASE4UnknownINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

October 31, 2014

Conditions
Diabetes MellitusCoronary Disease
Interventions
DRUG

Ticagrelor

Ticagrelor will be given (to patients with low response to clopidogrel randomized to the Ticagrelor group) at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient's treatment will be switched back to clopidogrel (to complete 1 year of treatment).

DRUG

Continued clopidogrel

Patients with low response to clopidogrel randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI

Trial Locations (1)

49100

Rabin Medical Center, Petah Tikva

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Tel Aviv Medical Center

OTHER

collaborator

Sheba Medical Center

OTHER_GOV

collaborator

Meir Medical Center

OTHER

collaborator

Rambam Health Care Campus

OTHER

lead

Rabin Medical Center

OTHER